Aristotle University Of Thessaloniki (AUTH)
Αποτελεσματικότητα και ασφάλεια χορήγησης της ριφαμπικίνης στην αντιμετώπιση της πειραματικής μόλυνσης του σκύλου με την Ehrlichia Canis
Abstract
dc:descriptionHistorically, tetracyclines are considered to be first-line drugs in the treatment of canine monocytic ehrlichiosis (CME) caused by Ehrlichia canis. However, only doxycycline has been critically evaluated in experimental or natural cases and current evidence implies that although doxycycline effectively ameliorates the E. canis-induced clinical and hematological abnormalities, it is not consistently effective in clearing the infection. In addition, some dogs may be intolerant to doxycycline,thus justifying the evaluation of medications that could be usedas alternatives to doxycycline. Recent data in a limited number of dog have indicated that rifampin may be effective in eliminating the infection in dogs experiencing the subclinical or chronic phase of the disease.There are currently no data on the potential effectiveness of rifampin in acute CME, while information on the potential adverse reactions of the drug in the dog is largely anecdotal.This study was undertaken to 1) evaluate the efficacy of rifampin in achieving clinical and hematological recovery and clearing the infection in dogs with experimental acute CME, 2) to compare the diagnostic sensitivity of three different tissues (blood, bone marrow, spleen) for the molecular (polymerase chain reaction, PCR) detection of E. canis DNA and 3) to investigate the potential clinical and clinicopathological abnormalities that may be associated with the dosing scheme selected in the current study.Sixteen Beagle dogs were enrolled in the study allocated into three groups. Group A (n=5) dogs were inoculated with the Israeli strain “611” of E. canis (propagated in DH82 cell culture) and treated with rifampin at 10mg/kg/24h, orally for 21 days (from 21-42 day post-inoculation, PID). All treated dogs were also given dexamethasone (0.5 mg/kgdexamethasone sodium, intravenously, once), 15 days after the completion of rifampin, to precipitate any latent E. canis infection. Group B (n=9) dogs were also inoculated with E. canisbut received no treatment (infected controls), while two dogs served as uninfected controls (Group C). For the duration of the study (terminated on 98 PID), the monitoring of the dogs was based on serial clinical examinations, complete blood counts, comprehensive serum biochemistry (including paired bile acid measurements), urinalysis, IgG-based indirect fluorescence antibody (IFA) testing and PCR for the detection of E. canis DNA in whole blood, bone marrow and splenic aspirates. Post inoculation, all infected dogs experienced clinical manifestations compatible with CME, whereas no difference was found in the median clinical score between infected treated and untreated dogs throughout the study. All infected dogs developed persistent thrombocytopenia until the 21PID. Treated dogs had significantly higher platelet counts compared to the infected untreated dogs on 42and 98 PID, whereas the time for normalization of the parameter appeared significantly shorter in the rifampin treated dogs compared to their infected untreated counterparts. All infected dogs seroconverted until the 21 PID, without significant difference between the two groups concerning the median value of the anti-E. canis IgG titre throughout the study. The DNA of E. canis was also detected in at least one tissue in all infected dogs by PCR by the 21 PID. On completion of the study, 3/5 and 6/9 dogs of the groups A and B, respectively, remained PCR positive. Bone marrow aspirates appeared to have the highest sensitivity compared to whole blood and spleenic tissue aspirates in determining the clearance status of the infection. The only appreciable clinical effect attributed to rifampin treatment was the discoloration of the urine, which appeared orange in all treated dogs treated during the entire treatment period, whereas the regimen used resulted in significantly increased concentration of serum bile acids and increased activity of alkaline phosphatase (ALP). In conclusion, rifampin, as used in this study, significantly hastened the resolutionof thrombocytopenia, but was inconsistent in eliminating the acute E. canisinfection. Urine discoloration, increased concentrations of serum bile acids and increased activity of ALP were the predominant clinical and clinicopathological abnormalities associated with rifampin treatment. Bone marrow appears to be of higher sensitivity for the PCR-based documentation of acute E. canis infection and clearing status of the infection may be optimized by molecular testing of an array of tissues (bone marrow, spleen and blood) at least 1-2 months post-treatment, so as to minimize the odds for obtaining false negative results.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theodorou, Konstantina
- Θεοδώρου, Κωνσταντίνα
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37399